Stifel raises Incyte stock price target on pipeline potential By Investing.com
Stifel has increased its price target for Incyte Corp. (NASDAQ: INCY) shares to $157 from $145, maintaining a Buy rating, citing the company's underappreciated first-in-class pipeline in gastrointestinal oncology and hematology. InvestingPro analysis suggests the stock is undervalued, and Stifel anticipates significant growth from the core business excluding Jakafi and Jakafi XR, projecting over $10 billion in peak worldwide sales from its late-stage pipeline. The report also mentions recent positive developments from other analysts, including H.C. Wainwright's increased price target due to FDA approval of Atebrioz and Cantor Fitzgerald's reiteration of a Neutral rating with positive remarks on Opzelura.
A $40,500 director retainer becomes 322 shares for Julian C. Baker at Incyte (INCY).
Incyte director Julian C. Baker acquired 322 shares of Incyte Common Stock on September 30, 2026. This acquisition was in lieu of quarterly director retainer fees of $40,500 and was made under the Amended and Restated 2010 Stock Incentive Plan, with the shares being fully vested. Baker Bros. Advisors LP maintains voting and dispositive power over these shares, and the acquisition involved an indirect pecuniary interest through associated funds.
203 shares replace director fees at Incyte (INCY), with the award fully vested.
Incyte director Paul J. Clancy acquired 203 fully vested restricted shares of INCY on September 30, 2026. These shares, valued at $121.35 each, were issued in lieu of quarterly director retainer fees under the company's 2010 Stock Incentive Plan. Following this transaction, Clancy's direct holdings in Incyte total 25,838 shares, including unvested restricted stock units.
Shares replace quarterly director fees as Incyte (INCY) awards 206 fully vested shares.
Incyte director Edmund Harrigan received 206 fully vested restricted shares on September 30, 2026, in lieu of quarterly director retainer fees. These shares, valued at $121.35 each, were issued under the company's 2010 Stock Incentive Plan and comply with Rule 10b5-1. Following this transaction, Harrigan's total holdings include 23,225 shares, with 1,642 representing unvested restricted stock units.
Wells Fargo Adjusts Price Target on Incyte to $128 From $116, Keeps Equalweight Rating
Wells Fargo has increased its price target for Incyte (INCY) to $128 from $116, while maintaining an Equalweight rating on the stock. According to analysts, Incyte currently holds an average rating of overweight with a mean price target of $129.65.
If You Invested $1000 In Incyte Stock 20 Years Ago, You Would Have This Much Today
Incyte (NASDAQ: INCY) has significantly outperformed the market over the last 20 years, achieving an average annual return of 17.52%. An initial investment of $1000 in Incyte stock two decades ago would now be worth $25,300.22. This demonstrates the powerful effect of compounded returns on investment growth over time.
INCY Maintained by Wells Fargo -- Price Target Raised to $128
Wells Fargo maintained an Equal-Weight rating on Incyte (INCY) and raised its price target from $116.00 to $128.00. While the company boasts a strong GF Score™ of 88/100 and financial health, GuruFocus indicates INCY is currently 14.8% overvalued at $121.35 compared to its GF Value™ of $105.74, and recent insider selling activity has been noted.
Wells Fargo Adjusts Price Target on Incyte to $128 From $116, Keeps Equalweight Rating
Wells Fargo has increased its price target for Incyte Corporation (INCY) to $128 from $116, while maintaining an "Equalweight" rating on the stock. This adjustment reflects an updated outlook on the biopharmaceutical company, which specializes in therapeutic products for cancers and inflammatory disorders.
Halozyme Therapeutics, Inc. Appoints James "Jim" Daly to Its Board of Directors
Halozyme Therapeutics, Inc. has announced the appointment of James "Jim" Daly to its Board of Directors. Mr. Daly is a highly experienced biopharmaceutical executive with over three decades of commercial leadership, including successful launches of respiratory, oncology, and immunology therapies. He has previously served on Halozyme's board and held senior commercial roles at Incyte Corporation, Amgen, and Glaxo Wellcome/GlaxoSmithKline.
Learn Why The Bull Case For Incyte (INCY) Could Change Following Rare Disease Drug Approval
Incyte (INCY) recently received FDA approval for Atebrioz (zilurgisertib), an oral ALK2 inhibitor for Fibrodysplasia Ossificans Progressiva, which also came with a Rare Pediatric Disease Priority Review Voucher. This approval, while positive, marginally influences Incyte's investment narrative, as the company still faces pressure to broaden its product mix beyond Jakafi and improve pipeline execution and cost discipline. Despite projected revenue of US$5.8 billion and earnings of US$1.2 billion by 2029, the long-term outlook remains challenged by aging patents and high R&D and SG&A costs.
Incyte Corp. stock underperforms Tuesday when compared to competitors
Incyte Corp. (INCY) stock fell 1.30% on Tuesday, closing at $123.20, while the broader market indices, the S&P 500 and Dow Jones Industrial Average, also experienced slight declines. The company's stock is currently 7.09% below its 52-week high of $132.60, achieved on July 28th.
Incyte Corp Lobbyists, 2019
This OpenSecrets.org page details Incyte Corp's lobbying activities in 2019, specifically listing the lobbyists they hired. The data shows that all three named lobbyists in 2019 previously worked in the federal government, indicating a "revolving door" phenomenon. The company hired Avenue Solutions and W Strategies for its lobbying efforts during that year.
MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary – Company Announcement
MiniMed (Nasdaq: MMED) has appointed Sheila Denton as its new General Counsel & Corporate Secretary. Denton brings over 25 years of experience from global pharmaceutical and biotech companies, including a recent role as General Counsel at Incyte. Her appointment is effective immediately, and she is expected to provide strong leadership as MiniMed continues its growth and transformation as an independent public company.
INCY Maintained by JP Morgan -- Price Target Raised to $123.00
JP Morgan has maintained a Neutral rating on Incyte (INCY), increasing its price target from $120.00 to $123.00. While Incyte exhibits strong financial health and profitability with a GF Score™ of 87/100, GuruFocus indicates it is 17.1% overvalued. Investors should consider this overvaluation and recent insider selling activity despite generally positive sentiment among institutional investors.
A legal chief with more than 25 years in pharma and biotech joins MiniMed.
MiniMed has appointed Sheila Denton as its new General Counsel and Corporate Secretary, effective immediately. Denton, who previously held similar roles at Incyte, brings over 25 years of experience in global pharmaceutical and biotech companies. She succeeds Courtney Nelson Wills, who departed MiniMed for other professional opportunities.
JPMorgan Adjusts Price Target on Incyte to $123 From $120, Keeps Neutral Rating
JPMorgan has updated its price target for Incyte (INCY) to $123 from $120, while maintaining a Neutral rating on the stock. The article mentions that Incyte currently holds an average analyst rating of "overweight" with a mean price target of $129.04.
H.C. Wainwright raises Incyte stock price target on Atebrioz approval By Investing.com
H.C. Wainwright has increased its price target for Incyte Corp. (NASDAQ: INCY) to $152 from $150, maintaining a Buy rating. This adjustment follows the FDA approval of Atebrioz (zilurgisertib) for fibrodysplasia ossificans progressiva patients, which triggers a $25 million payment to Incyte and the issuance of a Rare Pediatric Disease Priority Review Voucher. The firm anticipates a combined benefit of $225 million to $250 million from the milestone payment and voucher.
Incyte takes FDA approval for Atebrioz as first oral ALK2i for fibrodysplasia ossificans progressiva
Incyte (Nasdaq: INCY) and Mirum Pharmaceuticals (Nasdaq: MIRM) have received FDA approval for Atebrioz (zilurgisertib), the first oral ALK2 inhibitor for fibrodysplasia ossificans progressiva (FOP). The drug is approved to reduce new heterotopic ossification in patients aged 12 and older and is administered once daily. This approval was based on data from the PROGRESS study, showing a significant decrease in new HO lesion volume in treated patients compared to placebo.
H.C. Wainwright raises Incyte stock price target on Atebrioz approval By Investing.com
H.C. Wainwright has increased its price target for Incyte Corp. (NASDAQ: INCY) to $152 from $150, maintaining a Buy rating. This adjustment follows the FDA approval of Atebrioz (zilurgisertib) for fibrodysplasia ossificans progressiva patients, which is expected to bring Incyte a $25 million payment and a Rare Pediatric Disease Priority Review Voucher. The firm anticipates a combined benefit of $225 million to $250 million from the approval milestone and voucher.
HC Wainwright Adjusts Price Target on Incyte to $152 From $150, Maintains Buy Rating
HC Wainwright has adjusted its price target for Incyte (INCY) to $152 from $150, while reiterating a Buy rating on the stock. According to analysts, Incyte currently holds an average "overweight" rating with a mean price target of $129.13. This information is available as a premium article from MT Newswires.
JPMorgan Adjusts Price Target on Incyte to $123 From $120, Keeps Neutral Rating
JPMorgan has increased its price target for Incyte (INCY) to $123 from $120, while maintaining a Neutral rating on the stock. This adjustment comes amidst recent news for Incyte, including the US FDA approval of Atebrioz for a rare genetic ossification condition and various data presentations at medical congresses. The article notes that the full content is reserved for members.
Empery Digital Inc. SEC Filing (Sep 25, 2026)
ATG Capital announced that Institutional Shareholder Services Inc. (ISS) has recommended that Empery Digital Inc. stockholders vote for two of ATG Capital's nominees, Gabriel D. Gliksberg and Aaron T. Morris, to the Empery Digital Board of Directors. ISS also advised withholding support from incumbent directors Orn Olason and Ian Read and voting against the company's equity incentive plan at the upcoming October 14, 2026, Annual Meeting. ATG Capital, the largest non-affiliated stockholder with over 16% of shares, urges stockholders to vote for all four of its independent nominees, citing ISS's findings that the board's functioning has been "less than robust" and its rejection of ATG Capital's nominees was "unjustified."
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP patients 12 and older
Mirum Pharmaceuticals received FDA approval for Atebrioz to treat fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and older, with U.S. availability expected in October. The approval was based on a study showing a reduction in new bone lesion volume, despite missing a conventional statistical threshold for new lesion incidence. This marks the third FDA-approved treatment for FOP, and Mirum plans to offer patient support programs to facilitate access.
About 300 people in the U.S. have a disease that causes bone to form in soft tissues. FDA approves a treatment.
The FDA has approved Atebrioz™ (zilurgisertib), developed by Mirum Pharmaceuticals and Incyte, for adult and pediatric patients aged 12 and older with fibrodysplasia ossificans progressiva (FOP). This once-daily oral ALK2 inhibitor reduces the volume of new heterotopic ossification, a condition where bone forms in soft tissues. Atebrioz is expected to be available in the U.S. in October through Mirum Access Plus, with financial assistance for eligible patients, and Incyte also received a Rare Pediatric Disease Priority Review Voucher.
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals and Incyte have received U.S. FDA approval for Atebrioz™ (zilurgisertib) tablets for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) in patients aged 12 and older. This once-daily oral ALK2 inhibitor is designed to reduce the volume of total new heterotopic ossification, a key symptom of FOP. Atebrioz is expected to be available in the U.S. in October through the Mirum Access Plus (MAP) patient support program, with ongoing development for younger pediatric patients.
Form 4 Incyte Corporation For: 25 September By Investing.com
This article announces the filing of Form 4 for Incyte Corporation on September 25th. Form 4 is an SEC filing used to report changes in beneficial ownership of a company's securities by insiders. The article provides this information as a brief news update for investors.
Incyte Corporation (INCY) Stock Price Today: $125.74
Incyte Corporation (INCY) stock is currently trading at $124.39, down 2.0% in the past day, yet maintains a bullish technical outlook with a consensus price target of $130.07. The company reported strong Q2 2026 earnings, beating estimates, and revenue growth is projected to reach $5.14 billion in 2025. Despite upcoming exclusivity loss for JAKAFI after 2029, Incyte aims for $4 billion in sales, driven by pipeline expansion and strategic diversification.
Atossa CEO to join Harvard panel on aging disease drug development and regulatory strategies
Dr. Steven Quay, CEO of Atossa Therapeutics, will participate in a Harvard panel at the ARDD 2026 meeting to discuss the translation of aging research into new drug therapies and regulatory strategies. The discussion will cover clinical trial design, therapeutic development, and regulatory considerations in aging biology. This highlights Atossa's commitment to developing treatments for rare diseases based on strong biological evidence.
Incyte (INCY) withheld shares from its strategy chief for taxes at a reported $126.93 per share.
Incyte Corporation reported that its EVP, Chief Strategy Officer, David H. Gardner, had 920 common shares withheld on September 22, 2026, to cover tax withholding obligations related to previously reported restricted stock units. The shares were withheld at a price of $126.93 per share. Following this transaction, Gardner's direct position included 15,904 shares, with 14,467 of those still unvested.
Incyte (INCY) Stock Could Be 34% Above Fair Value After EADV Data
Incyte's stock has seen a significant multi-year run, prompting questions about its current valuation relative to future cash generation. Despite strong past performance and recent product news for therapies like Opzelura, a Discounted Cash Flow (DCF) analysis suggests the stock might be overvalued, with projections pointing to declining free cash flow in the early 2030s. Community narratives present both bull and bear cases, with some seeing continued upside from a diversified product portfolio and others highlighting increased costs from new acquisitions.
Did Early Trial Results Just Shift Disc Medicine (IRON) Stock Narrative?
Disc Medicine (IRON) recently announced positive early Phase 2 trial results for DISC-3405 in polycythemia vera, which showed improved iron regulation and reduced need for phlebotomy. This development strengthens Disc Medicine's investment narrative, focusing on real-world patient outcomes in hematology, alongside its other active program, selcodebart, for myelofibrosis. Despite these clinical successes, the company remains unprofitable and will need to finance its capital-intensive pipeline, making trial progression and funding access critical risk factors.
Analysts Offer Insights on NA Companies: Incyte (INCY) and Coherent Corp (COHR)
This article provides analyst insights on two NA sector companies: Incyte (INCY) and Coherent Corp (COHR). RBC Capital's Brian Abrahams maintained a Hold rating on Incyte with a $109.00 price target, while Stifel Nicolaus analyst Ruben Roy gave Coherent Corp a Buy rating with a $420.00 price target. Both companies currently have a Moderate Buy consensus among analysts.
"Inside DOGE" Launches Today as the First Book to Take Readers Inside the Department of Government Efficiency
Tyler Hassen, a Houston business executive and former Acting Assistant Secretary at the U.S. Department of the Interior, has released "Inside DOGE," a book offering an insider's account of the Department of Government Efficiency (DOGE) and its efforts to reform the federal government. The book, described as part memoir and part "management autopsy," details Hassen's experiences with the challenges and bureaucratic hurdles within Washington. Published by Republic Book Publisher, "Inside DOGE" is available on Amazon and through major booksellers.
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?
Incyte Corporation (INCY) is a large-cap biopharmaceutical company specializing in treatments for cancer, blood disorders, and immune-mediated diseases. The company's stock has shown strong performance recently, gaining 22.5% over the past three months and outperforming the State Street SPDR S&P Biotech ETF (XBI) in that period. Despite trailing XBI over longer timeframes, Incyte's growth outlook is robust, with significant sales increases and pipeline expansion.
Incyte to present inflammation and autoimmunity data at EADV
Incyte announced it will present data from its inflammation and autoimmunity portfolio at the European Academy of Dermatology and Venereology Congress. The presentations will cover treatments for conditions such as hidradenitis suppurativa, atopic dermatitis, and prurigo nodularis, including results from studies on ruxolitinib cream and povorcitinib. Ruxolitinib cream is already approved for certain conditions, while povorcitinib is currently under regulatory review and in Phase 3 trials for other uses.
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio
Incyte announced that it will present data from its Inflammation and Autoimmunity (IAI) portfolio at the European Academy of Dermatology and Venereology (EADV) 2026 Congress. The presentations will cover various skin conditions including atopic dermatitis, hidradenitis suppurativa, prurigo nodularis, and vitiligo, highlighting the company's commitment to advancing innovation in immune-mediated skin diseases. Key data include findings on Opzelura (ruxolitinib) cream and povorcitinib, emphasizing their efficacy and impact on patient quality of life.
Incyte will present research on eczema, vitiligo and painful skin conditions in Vienna
Incyte (Nasdaq: INCY) announced it will present data from its Inflammation and Autoimmunity portfolio at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria, from September 30 to October 3, 2026. The presentations will cover late-stage JAK programs and real-world experience with Opzelura across various immune-mediated skin diseases, including atopic dermatitis, hidradenitis suppurativa, prurigo nodularis, and vitiligo. This highlights Incyte's commitment to advancing treatments for these conditions and understanding the patient experience.
More than 1 million patients have used this skin cream. Partners plan to bring it to Australia.
Specialised Therapeutics (ST) and Incyte (INCY) have expanded their partnership to bring ruxolitinib cream (Opzelura®) to Australia for vitiligo and atopic dermatitis patients. ST will manage Australian regulatory, reimbursement, and commercial efforts, while Incyte handles development and manufacturing. Opzelura is already approved in the US and EU for these conditions, and over one million patients globally have used it.
Specialised Therapeutics expands Incyte partnership to Australia
Specialised Therapeutics has expanded its partnership with Incyte Biosciences International to commercialize ruxolitinib cream (Opzelura) in Australia. This cream is a topical Janus kinase inhibitor used for conditions like non-segmental vitiligo and atopic dermatitis. Specialised Therapeutics will handle regulatory submissions, marketing, and distribution in Australia, while Incyte remains responsible for development and manufacturing.
Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia
Specialised Therapeutics (ST) has expanded its partnership with Incyte to commercialize, distribute, and register ruxolitinib cream (Opzelura®) in Australia. This collaboration will focus on bringing the topical Janus kinase (JAK) inhibitor, used for treating non-segmental vitiligo and atopic dermatitis, to the Australian market. ST will manage regulatory submissions and distribution, aiming to address unmet medical needs for chronic skin conditions in the region.
Incyte Corp (INCY) Stock Price, Quote, News & History
This Benzinga article provides a comprehensive overview of Incyte Corp (INCY) stock, including its current price, key statistics, recent news, financial data, and analyst trends. It details the company's focus on small-molecule drugs, its leading product Jakafi, and its market performance. The article also lists competitors and addresses frequently asked questions about the stock.
What Is Incyte Corporation (NASDAQ:INCY) Signaling Through Its Pipeline?
This article examines Incyte Corporation (NASDAQ:INCY) through the lens of its commercial portfolio and clinical pipeline progress, emphasizing that durable demand and disciplined execution are more critical than short-term market sentiment. It discusses how the company's business fundamentals interact with broader market conditions, including monetary-policy expectations and easing oil prices, and highlights the importance of consistent execution, clear communication, and strategic alignment in the healthcare sector. The piece suggests that investors should focus on Incyte's operational exposure and strategic rigor rather than solely on macro themes.
Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum
Incyte (NASDAQ:INCY) is identified as a strong investment candidate by combining Mark Minervini's Trend Template with high-growth momentum criteria. The stock exhibits robust technical strength, including being in a Stage 2 uptrend with high relative strength, and strong fundamental growth with accelerating earnings and revenue. While the long-term trend is positive, the short-term trend is neutral, indicating a need for a confirmed breakout above resistance for optimal entry.
Electra amasses $350M in biotech’s latest big IPO
Electra Therapeutics successfully raised $350 million in its initial public offering, becoming the 21st biotech firm to price a new stock issuance in 2026. This IPO contributes to a significant trend, as 11 biotechs have now raised over $300 million each this year, matching 2021's total. The company plans to use the proceeds to advance its experimental drug, ipsoprubart, for the treatment of secondary hemophagocytic lymphohistiocytosis (HLH), which is currently in a registrational trial.
Charles Schwab, UnitedHealth, Cleveland-Cliffs: CNBC ‘Final Trades’ - Charles Schwab (NYSE:SCHW)
On CNBC's "Halftime Report Final Trades," experts provided their stock recommendations. Jenny Van Leeuwen Harrington picked The Charles Schwab Corporation (NYSE: SCHW), Jim Lebenthal recommended Cleveland-Cliffs Inc. (NYSE: CLF), Stephen Weiss named UnitedHealth Group Incorporated (NYSE: UNH), and Joseph M. Terranova selected Incyte Corporation (NASDAQ: INCY). Analyst ratings and recent stock performances for these companies were also highlighted.
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
William Blair initiated coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with an Outperform rating, anticipating its lead cancer drug, azenosertib, could achieve $1.3 billion in peak sales. The drug, an oral WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer, is expected to launch in 2028 with potential for accelerated approval based on positive Phase 2 DENALI trial results. Despite promising early data and improved tolerability over competitors, the company faces clinical, competitive, and funding risks.
MacroGenics at H.C. Wainwright conference: leaner model, rich pipeline
MacroGenics (MGNX) presented at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting a significant transformation towards a leaner operating model and a robust pipeline focused on antibody-drug conjugates, checkpoint therapy, and T-cell engagers. The company announced a substantial reduction in headcount, the sale of its CDMO business for $120 million, and a strong pro forma cash balance of $327 million with no debt, providing a runway through 2028. MacroGenics emphasized its reliance on non-dilutive funding through partnerships and milestones, showcasing promising early clinical data for several assets like MGC026 and lorigerlimab, and an expanded collaboration with Gilead.
Cantor Fitzgerald reiterates Neutral on Incyte stock on Opzelura use
Cantor Fitzgerald has reiterated a Neutral rating on Incyte (NASDAQ: INCY) shares, noting the strong market appeal and off-label use of its topical treatment Opzelura for hidradenitis suppurativa. Despite this, the firm maintains its rating following discussions with Incyte executives. The article also highlights Incyte's strong financial performance, its agreement with CMS for Jakafi pricing, and promising clinical trial results for its experimental cancer treatment.
Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today
Incyte (NASDAQ: INCY) has significantly outperformed the market over the last 20 years, achieving an average annual return of 17.44%. An initial investment of $1,000 in Incyte 20 years ago would now be worth $25,320.17, highlighting the substantial impact of compounded returns. The company currently holds a market capitalization of $24.69 billion.
Cantor Fitzgerald reiterates Neutral on Incyte stock after conference
Cantor Fitzgerald has maintained a Neutral rating on Incyte (NASDAQ: INCY) following an investor breakfast at their Global Healthcare Conference. Incyte's management reinforced its strategy to achieve $3 billion to $4 billion in durable core business revenue by 2030, excluding Jakafi, and to advance five key pipeline candidates, with the company expecting to end the year with approximately $4 billion in cash and no debt. InvestingPro suggests the stock is undervalued with an 8% free cash flow yield, while other recent developments include a voluntary agreement with CMS regarding Jakafi pricing and various analyst ratings changes based on competitive and experimental treatment news.
